Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Licenses Celera's Breast Cancer Receptor Patents

NEW YORK (GenomeWeb News) — Celera said today it has licensed its estrogen/progesterone receptor patents to LabCorp, which will use the IP to commercialize two cancer tests.
 
The reference lab giant will use one test to predict risk of metastasis in early-stage breast cancer, while the other will assess hormone-receptor status to help plan endocrine therapy.
 
Under the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of lab services and tests that use the IP.
 
Much of the IP related to this license are involved in p53 tumor suppressor signaling pathways and are implicated in cancer proliferation, Celera said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.